Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J-McNeil To Co-Promote Cephalon ADHD Treatment Modafinil

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Johnson & Johnson's McNeil Consumer & Specialty Pharma unit will add Cephalon's attention deficit/hyperactivity disorder treatment modafinil to its pediatric portfolio under a Sept. 1 co-promotion pact

You may also be interested in...

Cephalon modafinil "approvable" in ADHD

Cephalon is anticipating an early 2006 approval of Sparlon (modafinil, formerly Attenace) for attention deficit/hyperactivity disorder, the firm says Oct. 21. FDA deemed the agent "approvable" Oct. 20 for use in children and adolescents ages six to 17 years. The Sparlon NDA is based on three seven- to nine-week pivotal trials showing "significant improvement compared to placebo as early as the first week, with continued improvement during titration and dose maintenance," Cephalon says. The company announced an agreement in August to co-promote Sparlon with Johnson & Johnson's McNeil Consumer & Specialty Pharmaceuticals Division (1Pharmaceutical Approvals Monthly September 2005, p. 24)...

Cephalon Strategy: Four NDAs In 2005-2006 To Double Firm’s Size

Cephalon goal of four NDA submissions in 14 months is on-track, with approvals forecast to double size of company by 2008. Pediatric sales force of 250 to be hired to detail modafinil for ADHD, with debut slated for early 2006. FDA rejects trade name Attenace. OraVescent breakthrough cancer pain NDA slated for Q3 2005; Gabitril sNDA for generalized anxiety in Q1 2006

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts